Home›Companies›Rejuvenation Technologies Inc.
Rejuvenation Technologies Inc.

mRNA therapeutics to extend healthspan entering clinical trials

Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Reverses 10 years of telomere shortening with a single dose. Preclinical efficacy in fibrotic liver and lung disease. Entering IND-enabling. 50+ granted patents, 7 patent families. FDA INTERACT cleared.
Active Founders
Stanford PhD Genetics (2018)
John Ramunas, PhD, invented TERT mRNA telomere extension at Stanford in Helen Blau's lab — reversing a decade of telomere shortening in one treatment. 50+ granted patents across 7 families through 2046. Preclinical efficacy in 4 organ systems. FDA INTERACT cleared. Khosla Ventures seed. YC S18. Raising $10M seed extension ($2M wired) for 3 clinical trials — Phase I readout Q3 2027. Subject #1 in first human trial.
Rejuvenation Technologies Inc.
Founded:2018
Batch:Summer 2018
Team Size:7
Status:
Active
Location:San Francisco